Prevention of Disease Progression Throughout the Cardiovascular Continuum: The Role of Adrenergic β-blockade
Despite remarkable therapeutic achievements in medicine, cardiovascular diseases remain the major cause of death in the new millennium. The cardiovascular disease continuum starts with risk factors such as hypertension, diabetes mellitus and lipid disorders, leading to coronary artery disease or lef...
Gespeichert in:
| Weitere Verfasser: | |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
Berlin, Heidelberg
Springer Berlin Heidelberg
2001
|
| Schlagworte: | |
| Online-Zugang: | UBR01 Volltext |
| Zusammenfassung: | Despite remarkable therapeutic achievements in medicine, cardiovascular diseases remain the major cause of death in the new millennium. The cardiovascular disease continuum starts with risk factors such as hypertension, diabetes mellitus and lipid disorders, leading to coronary artery disease or left ventricular hypertrophy. Left ventricular dysfunction and remodelling follow after initial myocardial damage (e.g. myocardial infarction), finally leading to the development of heart failure. This book gives an overview of the effects of antiadrenergic treatment in the different stages of the cardiovascular continuum, with a particular emphasis on heart failure, authored by a faculty of leading international clinical cardiologists |
| Beschreibung: | 1 Online-Ressource (IX, 147 p) |
| ISBN: | 9783642565250 |
| DOI: | 10.1007/978-3-642-56525-0 |
Internformat
MARC
| LEADER | 00000nmm a2200000zc 4500 | ||
|---|---|---|---|
| 001 | BV046143915 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 190905s2001 |||| o||u| ||||||eng d | ||
| 020 | |a 9783642565250 |9 978-3-642-56525-0 | ||
| 024 | 7 | |a 10.1007/978-3-642-56525-0 |2 doi | |
| 035 | |a (ZDB-2-SME)978-3-642-56525-0 | ||
| 035 | |a (OCoLC)1118997506 | ||
| 035 | |a (DE-599)BVBBV046143915 | ||
| 040 | |a DE-604 |b ger |e aacr | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-355 | ||
| 082 | 0 | |a 616.12 |2 23 | |
| 084 | |a YB 9500 |0 (DE-625)153178:12905 |2 rvk | ||
| 245 | 1 | 0 | |a Prevention of Disease Progression Throughout the Cardiovascular Continuum |b The Role of Adrenergic β-blockade |c edited by Lars E. Rydén |
| 264 | 1 | |a Berlin, Heidelberg |b Springer Berlin Heidelberg |c 2001 | |
| 300 | |a 1 Online-Ressource (IX, 147 p) | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 520 | |a Despite remarkable therapeutic achievements in medicine, cardiovascular diseases remain the major cause of death in the new millennium. The cardiovascular disease continuum starts with risk factors such as hypertension, diabetes mellitus and lipid disorders, leading to coronary artery disease or left ventricular hypertrophy. Left ventricular dysfunction and remodelling follow after initial myocardial damage (e.g. myocardial infarction), finally leading to the development of heart failure. This book gives an overview of the effects of antiadrenergic treatment in the different stages of the cardiovascular continuum, with a particular emphasis on heart failure, authored by a faculty of leading international clinical cardiologists | ||
| 650 | 4 | |a Cardiology | |
| 650 | 4 | |a Cardiology | |
| 650 | 0 | 7 | |a Beta-Blocker |0 (DE-588)4006088-3 |2 gnd |9 rswk-swf |
| 655 | 7 | |0 (DE-588)4143413-4 |a Aufsatzsammlung |2 gnd-content | |
| 689 | 0 | 0 | |a Beta-Blocker |0 (DE-588)4006088-3 |D s |
| 689 | 0 | |5 DE-604 | |
| 700 | 1 | |a Rydén, Lars E. |4 edt | |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9783540415039 |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9783642625671 |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9783642565267 |
| 856 | 4 | 0 | |u https://doi.org/10.1007/978-3-642-56525-0 |x Verlag |z URL des Erstveröffentlichers |3 Volltext |
| 912 | |a ZDB-2-SME | ||
| 940 | 1 | |q ZDB-2-SME_1990/2004 | |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-031524098 | ||
| 966 | e | |u https://doi.org/10.1007/978-3-642-56525-0 |l UBR01 |p ZDB-2-SME |q ZDB-2-SME_1990/2004 |x Verlag |3 Volltext | |
Datensatz im Suchindex
| _version_ | 1804180478615355392 |
|---|---|
| any_adam_object | |
| author2 | Rydén, Lars E. |
| author2_role | edt |
| author2_variant | l e r le ler |
| author_facet | Rydén, Lars E. |
| building | Verbundindex |
| bvnumber | BV046143915 |
| classification_rvk | YB 9500 |
| collection | ZDB-2-SME |
| ctrlnum | (ZDB-2-SME)978-3-642-56525-0 (OCoLC)1118997506 (DE-599)BVBBV046143915 |
| dewey-full | 616.12 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 616 - Diseases |
| dewey-raw | 616.12 |
| dewey-search | 616.12 |
| dewey-sort | 3616.12 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| doi_str_mv | 10.1007/978-3-642-56525-0 |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>02483nmm a2200469zc 4500</leader><controlfield tag="001">BV046143915</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">190905s2001 |||| o||u| ||||||eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9783642565250</subfield><subfield code="9">978-3-642-56525-0</subfield></datafield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/978-3-642-56525-0</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-2-SME)978-3-642-56525-0</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1118997506</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV046143915</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">aacr</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-355</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">616.12</subfield><subfield code="2">23</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">YB 9500</subfield><subfield code="0">(DE-625)153178:12905</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Prevention of Disease Progression Throughout the Cardiovascular Continuum</subfield><subfield code="b">The Role of Adrenergic β-blockade</subfield><subfield code="c">edited by Lars E. Rydén</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Berlin, Heidelberg</subfield><subfield code="b">Springer Berlin Heidelberg</subfield><subfield code="c">2001</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource (IX, 147 p)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Despite remarkable therapeutic achievements in medicine, cardiovascular diseases remain the major cause of death in the new millennium. The cardiovascular disease continuum starts with risk factors such as hypertension, diabetes mellitus and lipid disorders, leading to coronary artery disease or left ventricular hypertrophy. Left ventricular dysfunction and remodelling follow after initial myocardial damage (e.g. myocardial infarction), finally leading to the development of heart failure. This book gives an overview of the effects of antiadrenergic treatment in the different stages of the cardiovascular continuum, with a particular emphasis on heart failure, authored by a faculty of leading international clinical cardiologists</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cardiology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cardiology</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Beta-Blocker</subfield><subfield code="0">(DE-588)4006088-3</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="0">(DE-588)4143413-4</subfield><subfield code="a">Aufsatzsammlung</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Beta-Blocker</subfield><subfield code="0">(DE-588)4006088-3</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Rydén, Lars E.</subfield><subfield code="4">edt</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9783540415039</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9783642625671</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9783642565267</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1007/978-3-642-56525-0</subfield><subfield code="x">Verlag</subfield><subfield code="z">URL des Erstveröffentlichers</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-2-SME</subfield></datafield><datafield tag="940" ind1="1" ind2=" "><subfield code="q">ZDB-2-SME_1990/2004</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-031524098</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1007/978-3-642-56525-0</subfield><subfield code="l">UBR01</subfield><subfield code="p">ZDB-2-SME</subfield><subfield code="q">ZDB-2-SME_1990/2004</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield></record></collection> |
| genre | (DE-588)4143413-4 Aufsatzsammlung gnd-content |
| genre_facet | Aufsatzsammlung |
| id | DE-604.BV046143915 |
| illustrated | Not Illustrated |
| indexdate | 2024-07-10T08:36:24Z |
| institution | BVB |
| isbn | 9783642565250 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-031524098 |
| oclc_num | 1118997506 |
| open_access_boolean | |
| owner | DE-355 DE-BY-UBR |
| owner_facet | DE-355 DE-BY-UBR |
| physical | 1 Online-Ressource (IX, 147 p) |
| psigel | ZDB-2-SME ZDB-2-SME_1990/2004 ZDB-2-SME ZDB-2-SME_1990/2004 |
| publishDate | 2001 |
| publishDateSearch | 2001 |
| publishDateSort | 2001 |
| publisher | Springer Berlin Heidelberg |
| record_format | marc |
| spelling | Prevention of Disease Progression Throughout the Cardiovascular Continuum The Role of Adrenergic β-blockade edited by Lars E. Rydén Berlin, Heidelberg Springer Berlin Heidelberg 2001 1 Online-Ressource (IX, 147 p) txt rdacontent c rdamedia cr rdacarrier Despite remarkable therapeutic achievements in medicine, cardiovascular diseases remain the major cause of death in the new millennium. The cardiovascular disease continuum starts with risk factors such as hypertension, diabetes mellitus and lipid disorders, leading to coronary artery disease or left ventricular hypertrophy. Left ventricular dysfunction and remodelling follow after initial myocardial damage (e.g. myocardial infarction), finally leading to the development of heart failure. This book gives an overview of the effects of antiadrenergic treatment in the different stages of the cardiovascular continuum, with a particular emphasis on heart failure, authored by a faculty of leading international clinical cardiologists Cardiology Beta-Blocker (DE-588)4006088-3 gnd rswk-swf (DE-588)4143413-4 Aufsatzsammlung gnd-content Beta-Blocker (DE-588)4006088-3 s DE-604 Rydén, Lars E. edt Erscheint auch als Druck-Ausgabe 9783540415039 Erscheint auch als Druck-Ausgabe 9783642625671 Erscheint auch als Druck-Ausgabe 9783642565267 https://doi.org/10.1007/978-3-642-56525-0 Verlag URL des Erstveröffentlichers Volltext |
| spellingShingle | Prevention of Disease Progression Throughout the Cardiovascular Continuum The Role of Adrenergic β-blockade Cardiology Beta-Blocker (DE-588)4006088-3 gnd |
| subject_GND | (DE-588)4006088-3 (DE-588)4143413-4 |
| title | Prevention of Disease Progression Throughout the Cardiovascular Continuum The Role of Adrenergic β-blockade |
| title_auth | Prevention of Disease Progression Throughout the Cardiovascular Continuum The Role of Adrenergic β-blockade |
| title_exact_search | Prevention of Disease Progression Throughout the Cardiovascular Continuum The Role of Adrenergic β-blockade |
| title_full | Prevention of Disease Progression Throughout the Cardiovascular Continuum The Role of Adrenergic β-blockade edited by Lars E. Rydén |
| title_fullStr | Prevention of Disease Progression Throughout the Cardiovascular Continuum The Role of Adrenergic β-blockade edited by Lars E. Rydén |
| title_full_unstemmed | Prevention of Disease Progression Throughout the Cardiovascular Continuum The Role of Adrenergic β-blockade edited by Lars E. Rydén |
| title_short | Prevention of Disease Progression Throughout the Cardiovascular Continuum |
| title_sort | prevention of disease progression throughout the cardiovascular continuum the role of adrenergic β blockade |
| title_sub | The Role of Adrenergic β-blockade |
| topic | Cardiology Beta-Blocker (DE-588)4006088-3 gnd |
| topic_facet | Cardiology Beta-Blocker Aufsatzsammlung |
| url | https://doi.org/10.1007/978-3-642-56525-0 |
| work_keys_str_mv | AT rydenlarse preventionofdiseaseprogressionthroughoutthecardiovascularcontinuumtheroleofadrenergicbblockade |